Superior Planning, LLC’s NewAmsterdam Pharma NAMS Stock Holding History

Superior Planning, LLC’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.02K	Buy	+124	New	+$3.43K	﹤0.01%	1405

Other funds holding NAMS

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Superior Planning, LLC's NAMS Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in NewAmsterdam Pharma (NAMS) in Q3 2026: 124 shares worth $3.02K. The stake represents ﹤0.01% of the portfolio and ranks #1405 among its holdings.

91 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

Superior Planning, LLC held 124 shares of NewAmsterdam Pharma worth $3.02K as of Q3 2026.
NewAmsterdam Pharma was a new Superior Planning, LLC position in Q3 2026.
NewAmsterdam Pharma made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1405 holding.
91 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.